Superstring Capital Sells $6.6M Stake in UroGen After Stock Surges Over 600%
Superstring Capital Management sold approximately 331,000 shares of UroGen Pharma Ltd., valued at around $6.64 million based on average quarterly pricing for Q1 2026. The sale reduced the fund's position in UroGen by nearly $9.86 million when accounting for both share sales and price changes.
Tickers: $URGN
Topics: biotech SEC filings stock sales